Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
NCT ID: NCT07243067
Last Updated: 2025-12-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
300 participants
OBSERVATIONAL
2026-01-15
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
NCT02664883
NANOTECH RCC Biomarkers
NCT02923284
The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
NCT02450448
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
NCT02499458
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
NCT02279004
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Clear-cell RCC
Participants with clear-cell RCC
Proteomic profiling of urinary EVs
EV isolation and mass spectrometry.
Blood sample collection
Blood samples collected pre- and post-nephrectomy
Papillary RCC
Participants with papillary RCC
Proteomic profiling of urinary EVs
EV isolation and mass spectrometry.
Blood sample collection
Blood samples collected pre- and post-nephrectomy
Chromophobe RCC
Participants with chromophobe RCC
Proteomic profiling of urinary EVs
EV isolation and mass spectrometry.
Blood sample collection
Blood samples collected pre- and post-nephrectomy
Benign Renal Tumor
Participants with benign renal tumors
Proteomic profiling of urinary EVs
EV isolation and mass spectrometry.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Proteomic profiling of urinary EVs
EV isolation and mass spectrometry.
Blood sample collection
Blood samples collected pre- and post-nephrectomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High-risk renal cell carcinoma (RCC) per American Urological Association (AUA) guidelines
* Scheduled to undergo nephrectomy
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabrice Lucien-Matteoni, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HT9425-25-1-0607
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
25-003121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.